Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
GlaxoSmithKline will pay Ideaya Bioscience $100 million to gain access to three cancer drug–discovery programs. The deal, which includes an equity stake in the biotech worth $20 million, centers on finding drugs that exploit the concept of synthetic lethality, wherein a cancer cell can survive without one gene but dies if a second gene is crippled. GSK is buying into three synthetic lethality targets—MAT2A, Pol Theta, and Werner Helicase—for which Ideaya says it has solved crystal structures and made preclinical progress.
This article has been sent to the following recipient: